C5AR1 and neoplasm: This combination strategy aims to reduce immunosuppressive C5a signaling in the tumor microenvironment, where C5a recruits myeloid-derived suppressor cells and inhibits CD8+ T cell function (233), thereby potentiating the efficacy of ICIs.